These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

546 related items for PubMed ID: 23934461

  • 1. Transarterial chemoembolization for treatment of hepatocellular carcinoma: A single center experience.
    Idilman I, Peynircioğlu B, Cil BE, Doğanay Erdoğan B, Yalçın S, Bayraktar Y, Kav T, Altundağ K, Balkancı F.
    Turk J Gastroenterol; 2013; 24(2):141-7. PubMed ID: 23934461
    [Abstract] [Full Text] [Related]

  • 2. Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival.
    Mouli SK, Hickey R, Thornburg B, Sato KT, Desai K, Gabr A, Kallini JR, Niemeri H, Kircher S, Mulcahy MF, Benson Iii AB, Gupta R, Salem R, Lewandowski RJ.
    J Vasc Interv Radiol; 2016 Sep; 27(9):1279-1287. PubMed ID: 27062355
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ, Dhanasekaran R, El-Rayes BF, Kauh JS, Maithel SK, Chen Z, Kim HS.
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.
    Gomes AS, Monteleone PA, Sayre JW, Finn RS, Sadeghi S, Tong MJ, Britten CD, Busuttil RW.
    AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059
    [Abstract] [Full Text] [Related]

  • 5. Outpatient Transarterial Chemoembolization of Hepatocellular Carcinoma: Review of a Same-Day Discharge Strategy.
    Fritsche MR, Watchmaker JM, Lipnik AJ, Baker JC, Geevarghese S, Banovac F, Omary RA, Brown DB.
    J Vasc Interv Radiol; 2018 Apr; 29(4):550-555. PubMed ID: 29478795
    [Abstract] [Full Text] [Related]

  • 6. Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases.
    Makary MS, Kapke J, Yildiz V, Pan X, Dowell JD.
    J Vasc Interv Radiol; 2016 Sep; 27(9):1298-1304. PubMed ID: 27499157
    [Abstract] [Full Text] [Related]

  • 7. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A, Teiler J, Haji M, Seth E, Brismar TB, Wahlin S, Axelsson R, Stål P.
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [Abstract] [Full Text] [Related]

  • 8. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C, Unterpaintner E, Goessmann H, Schlitt HJ, Mueller-Schilling M, Wohlgemuth WA, Stroszczynski C, Wiggermann P.
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [Abstract] [Full Text] [Related]

  • 9. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J, van Malenstein H, Vandecaveye V, Nevens F, van Pelt J, Heye S, Laleman W, Van Steenbergen W, Vaninbroukx J, Verslype C, Maleux G.
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [Abstract] [Full Text] [Related]

  • 10. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
    Hickey R, Mouli S, Kulik L, Desai K, Thornburg B, Ganger D, Baker T, Abecassis M, Ralph Kallini J, Gabr A, Gates VL, Benson Iii AB, Lewandowski RJ, Salem R.
    J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
    [Abstract] [Full Text] [Related]

  • 11. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS, Li HZ, Ma C, Xiao YD.
    BMC Cancer; 2019 Nov 29; 19(1):1162. PubMed ID: 31783814
    [Abstract] [Full Text] [Related]

  • 12. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
    Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Stauber R, Grünberger B, Müller C, Kölblinger C, Peck-Radosavljevic M, Sieghart W.
    Radiology; 2012 May 29; 263(2):590-9. PubMed ID: 22438359
    [Abstract] [Full Text] [Related]

  • 13. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B, Zhou J, Ling G, Zhu D, Long Q.
    World J Surg Oncol; 2018 Mar 27; 16(1):69. PubMed ID: 29587773
    [Abstract] [Full Text] [Related]

  • 14. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival.
    Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, Yoon JH, Lee HS, Kim YJ.
    Radiology; 2011 Feb 27; 258(2):627-34. PubMed ID: 21273524
    [Abstract] [Full Text] [Related]

  • 15. Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion.
    Duan F, Wang EQ, Lam MG, Abdelmaksoud MH, Louie JD, Hwang GL, Kothary N, Kuo WT, Hofmann LV, Sze DY.
    Radiology; 2016 Feb 27; 278(2):612-21. PubMed ID: 26334787
    [Abstract] [Full Text] [Related]

  • 16. Safety and Efficacy of Transarterial Chemoembolization Combined with CT-Guided Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to the Hepatic Hilum within Milan Criteria.
    Guo Y, Zhang Y, Huang J, Chen X, Huang W, Shan H, Zhu K.
    J Vasc Interv Radiol; 2016 Apr 27; 27(4):487-95. PubMed ID: 26922006
    [Abstract] [Full Text] [Related]

  • 17. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma.
    Facciorusso A, Mariani L, Sposito C, Spreafico C, Bongini M, Morosi C, Cascella T, Marchianò A, Camerini T, Bhoori S, Brunero F, Barone M, Mazzaferro V.
    J Gastroenterol Hepatol; 2016 Mar 27; 31(3):645-53. PubMed ID: 26331807
    [Abstract] [Full Text] [Related]

  • 18. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS, Lin CY, Chuang MT, Lin CY, Tsai YS, Wang CK, Ou MC.
    BMC Gastroenterol; 2018 Aug 03; 18(1):124. PubMed ID: 30075752
    [Abstract] [Full Text] [Related]

  • 19. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, Pitton MB.
    BMC Cancer; 2015 Jun 10; 15():465. PubMed ID: 26059447
    [Abstract] [Full Text] [Related]

  • 20. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept.
    Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J.
    J Vasc Interv Radiol; 2018 Jun 10; 29(6):850-857.e1. PubMed ID: 29548875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.